Proximagen Group plc acquired by Upsher-Smith Laboratories, Inc.
Proximagen and Altacor sign agreement for 5HT2c.
Proximagen signs a strategic partnership agreement with H. Lundbeck A/S, involving a £10.3m investment in Proximagen by Lundbeck.
Proximagen acquires two CNS drug development programmes from GlaxoSmithKline.
Proximagen Neuroscience plc changes its name to Proximagen Group plc.
Proximagen sub-licences the North American rights to tonabersat to Upsher-Smith Laboratories Inc.
Proximagen acquires Minster Pharmaceuticals plc.
Proximagen announces a cash offer for Minster Pharmaceuticals plc which has two clinical stage assets, tonabersat and sabcomeline. Worldwide rights to both compounds were acquired by Minster from GlaxoSmithKline and these compounds benefit from comprehensive safety tolerance data following investment by GSK.
Proximagen makes its first corporate acquisition and buys Cambridge Biotechnology Limited from Biovitrum AB. The Company also acquires certain pre-clinical and clinical stage assets from Biovitrum A.B.
Proximagen acquires the compound naluzotan, the safety and tolerability of which has been demonstrated in the clinic. The Company is now exploring the potential of this compound for treating both epilepsy and levodopa-induced dyskinesia.
The Company raises £50 million in the first stage of its plan to become one of the world's leading companies developing therapeutics for patients suffering from diseases of the CNS. Funds are earmarked for the acquisition and development of clinical stage CNS programmes.
Proximagen signs a $232 million licensing agreement with Upsher-Smith Laboratories, Inc. for its lead programme, PRX1, which includes a $6 million equity investment in Proximagen.
Proximagen Neuroscience plc undertakes an Initial Public Offering raising £13.5m (gross) to fund the development of the Company's early stage drug discovery programmes which were centred on neurodegenerative disease. The Company's shares are listed on the AIM market of the London Stock Exchange.
Proximagen receives financial backing from IP Group plc, one of the UK's leading companies focusing on the commercialisation of intellectual property originating from research intensive institutions.
Proximagen Limited is founded. The company was a spin-out from King's College London and was built around the work of Professor Peter Jenner, a key opinion leader in the field of Parkinson's disease.